LLY

817.59

-1.55%↓

UNH

566.44

+0.03%↑

JNJ

159.98

+0.01%↑

NVO

111.95

+0.05%↑

ABBV

203.23

-0.43%↓

LLY

817.59

-1.55%↓

UNH

566.44

+0.03%↑

JNJ

159.98

+0.01%↑

NVO

111.95

+0.05%↑

ABBV

203.23

-0.43%↓

LLY

817.59

-1.55%↓

UNH

566.44

+0.03%↑

JNJ

159.98

+0.01%↑

NVO

111.95

+0.05%↑

ABBV

203.23

-0.43%↓

LLY

817.59

-1.55%↓

UNH

566.44

+0.03%↑

JNJ

159.98

+0.01%↑

NVO

111.95

+0.05%↑

ABBV

203.23

-0.43%↓

LLY

817.59

-1.55%↓

UNH

566.44

+0.03%↑

JNJ

159.98

+0.01%↑

NVO

111.95

+0.05%↑

ABBV

203.23

-0.43%↓

Search

Insulet Corp

Cerrado

Sector Salud

235.44 1.64

Resumen

Variación precio

24h

Actual

Mínimo

227.97

Máximo

236.35

Métricas clave

By Trading Economics

Ingresos

137M

189M

Ventas

47M

489M

P/B

Media del Sector

60.6

106.547

BPA

0.55

Margen de beneficio

38.608

Empleados

3,000

EBITDA

-3.1M

81M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

+7.67 upside

Dividendos

By Dow Jones

Próximas Ganancias

7 nov 2024

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

448M

16B

Apertura anterior

233.8

Cierre anterior

235.44

Noticias sobre sentimiento de mercado

By Acuity

27%

73%

76 / 389 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Weak Bearish Evidence

Insulet Corp Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

30 nov 2023, 17:43 UTC

Ganancias

Salesforce, Insulet, and Datadog Are November's Top Performers -- and These Are the Worst -- Barrons.com

17 nov 2023, 12:00 UTC

Principales Noticias

Obesity Drugs Put These Stocks on a Crash Diet, and Now They're Rebounding -- Heard on the Street -- WSJ

Comparación entre iguales

Cambio de precio

Insulet Corp Esperado

Precio Objetivo

By TipRanks

7.67% repunte

Estimación a 12 meses

Media 249.29 USD  7.67%

Máximo 285 USD

Mínimo 185 USD

De acuerdo con 17 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Insulet Corp Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

17 ratings

14

Comprar

3

Mantener

0

Vender

Puntuación técnica

By Trading Central

229.13 / 236.59Soporte y Resistencia

Corto Plazo

Weak Bearish Evidence

Medio plazo

Weak Bearish Evidence

Largo Plazo

Weak Bullish Evidence

Sentimiento

By Acuity

76 / 389 Clasificación en Salud

Noticias sobre sentimiento de mercado

Coyuntura alcista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Insulet Corp

Insulet Corporation is primarily engaged in the development, manufacture and sale of its proprietary Omnipod System, a continuous insulin delivery system for people with insulin-dependent diabetes. The Omnipod System includes the Omnipod Insulin Management System (Omnipod), the Omnipod DASHTM Insulin Management System (Omnipod DASH) and its digital mobile Omnipod platform. The Omnipod System features two devices: a small, lightweight, self-adhesive disposable tubeless Omnipod device (Pod) and a Personal Diabetes Manager (PDM). Users has to fill the Pod with insulin and wear directly on the body. It can be worn in multiple locations, including the abdomen, hip, back of upper arm, upper thigh or lower back. The Pod delivers precise, personalized doses of insulin into the body through a small flexible tube, cannula. PDM is a wireless, handheld device that programs the Pod with the user’s personalized insulin-delivery instructions and wirelessly monitors the Pod’s operation.